mentioned above; purifying it, and subjecting it to steps involving at least a reducing agent, an ionic detergent and/or a neutral detergent in conditions leading to a glycoprotein having said properties.

Please add the following as the brief description of the figure section on page 5, after line 20:

BRIEF DESCRIPTION OF THE FIGURE

The figure represents the SDS PAGE analysis under reducing conditions obtained with a recombinantly produced gp160 that was purified and treated to make trimers (lanes 3-4) compared to gp160 dimers (lane 2), monomers (lane 5 and 6), and combination of dimmers, trimers, and tetramers (lane 7).

In the claims:

Please amend claims 11, 13 and 16-19 as follows:

11. (Amended) A composition comprising a purified trimer of HIV gp160, wherein the trimer:

a) binds to CD4;

b) binds to an anti-gp120 antibody capable of neutralizing HIV infection of cells *in vitro*;

c) binds to an anti-gp41 antibody; and

d) has no inter-chain disulfide bridges.

13. (Amended) A composition comprising a trimer of HIV gp160 wherein all or a portion of the gp160 transmembrane region is deleted, and were the trimer:

e) binds to CD4;

f) binds to an anti-gp120 antibody capable of neutralizing HIV infection of cells *in vitro*;

g) binds to an anti-gp41 antibody; and

h) has no inter-chain disulfide bridges.

16. (Amended) The composition of any one of claims 11 - 13 further comprising an adjuvant.

17. (Amended) The composition according to claim 16 wherein the trimer is the only HIV surface antigen in the composition.

18. (Amended) A method of producing the trimer according to any one of claims 11 - 12, the method comprising, in order:

a) expressing gp160;

b) purifying the gp160;

c) contacting the gp160 with a reducing agent;